More Blasts Of Concern Over ROCKET-AF

The controversy over the big Xarelto trial does not appear to be going away. A new investigation published in the BMJ raises more troubling questions about the ROCKET-AF trial, which compared the novel oral anticoagulant rivaroxaban (Xarelto, Johnson & Johnson) to warfarin in patients with atrial fibrillation. The controversy about the trial first unfolded last...Click here to continue reading...

Source: CardioBrief - September 28, 2016 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Alere BMJ INR rivaroxaban ROCKET-AF Xarelto Source Type: blogs